Scientists Break 50-Year Bottleneck to Boost Doxorubicin Production

An international team engineered a bacterial strain that produces 180% more doxorubicin than current industrial methods.

Researchers identified redox partners Fdx4 and FdR3, a drug‑binding protein DnrV, and the DoxA enzyme structure as production bottlenecks.

The discoveries enabled strain engineering and led to the formation of spin‑out Meta-Cells Oy to develop the biosynthetic process.